GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Valuation Rank

X4 Pharmaceuticals (FRA:48Q) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

X4 Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

X4 Pharmaceuticals (FRA:48Q) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Valuation Rank
Comparable Companies
TALS ANNX PBYI CTXR XBIT INMB TNYA CARM TRVI LBPH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XFOR:USA 48Q:Germany
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
Website
https://www.x4pharma.com
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.